CHOLYBAR Drug Patent Profile

When do Cholybar patents expire, and when can generic versions of Cholybar launch?

Cholybar is a drug marketed by Parke Davis and is included in two NDAs.

The generic ingredient in CHOLYBAR is cholestyramine. There are eight drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the cholestyramine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Cholybar

A generic version of CHOLYBAR was approved as cholestyramine by EPIC PHARMA LLC on August 15^th, 1996.

Summary for CHOLYBAR

US Patents:	0
Applicants:	1
NDAs:	2
Clinical Trials:	2
DailyMed Link:	CHOLYBAR at DailyMed

Recent Clinical Trials for CHOLYBAR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
City of Hope Medical Center	Phase 1
National Cancer Institute (NCI)	Phase 1
National Cancer Institute (NCI)	Phase 2

See all CHOLYBAR clinical trials

US Patents and Regulatory Information for CHOLYBAR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Parke Davis	CHOLYBAR	cholestyramine	BAR, CHEWABLE;ORAL	071621-001	May 26, 1988		DISCN	No	No
Parke Davis	CHOLYBAR	cholestyramine	BAR, CHEWABLE;ORAL	071739-001	May 26, 1988		DISCN	No	No

Expired US Patents for CHOLYBAR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Parke Davis	CHOLYBAR	cholestyramine	BAR, CHEWABLE;ORAL	071621-001	May 26, 1988
Parke Davis	CHOLYBAR	cholestyramine	BAR, CHEWABLE;ORAL	071739-001	May 26, 1988

International Patents for CHOLYBAR

See the table below for patents covering CHOLYBAR around the world.

Country	Patent Number	Title	Estimated Expiration
Norway	865202
South Korea	900007468
China	1010549
Japan	S62155212	SWEET DELIVERY SYSTEM FOR ACTIVE SUBSTANCE
Portugal	83976	PROCESSO DE CONFEITARIA PARA A PREPARACAO DE UM SISTEMA PARA LIBERTACAO DE PRODUTOS ACTIVOS
China	86108429

CHOLYBAR Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory of Cholybar and Similar Cholesterol-Reducing Drugs

Introduction

Cholybar, a cholesterol-reducing drug, was part of a class of medications that once dominated the pharmaceutical market but has since been largely superseded by more innovative and effective treatments. To understand the market dynamics and financial trajectory of Cholybar and similar drugs, we need to delve into the historical context, market competition, and the evolution of cholesterol-reducing therapies.

Historical Context of Cholybar

Cholybar was one of the early cholesterol-reducing drugs introduced in the late 20th century. It belonged to a class of drugs that were initially seen as breakthroughs in managing cholesterol levels but later faced significant competition and eventual decline.

Market Competition and Supersession

Early Success and Market Capture

In the late 1980s, drugs like Mevacor (lovastatin) and Cholybar were among the first to capture a significant portion of the cholesterol-reducing drug market. Mevacor, for instance, quickly gained market share, capturing 42% of the market in less than 18 months[4].

Supersession by Newer Drugs

However, the success of these early drugs was short-lived. Newer, more effective statins like Zocor (simvastatin) and Lipitor (atorvastatin) soon entered the market, offering better efficacy and safety profiles. These newer drugs decimated the market share of earlier drugs like Cholybar and Mevacor. By 2001, Mevacor controlled less than 1% of the statin market, a fate likely shared by Cholybar[4].

Financial Trajectory

Peak Revenue and Decline

During their peak, cholesterol-reducing drugs were among the top-selling pharmaceuticals. For example, statins became the nation's pharmaceutical sales leaders, with over $11 billion in annual sales in the U.S. alone[4]. However, as newer drugs entered the market, the revenue from older drugs like Cholybar declined significantly.

Impact of Generic Competition

The introduction of generic versions of these drugs further eroded their market share and revenue. Generic competition, while significant, was not the primary cause of revenue loss. Instead, it was the introduction of more innovative and effective brand-name drugs that led to the decline of older medications[4].

Market Dynamics

Consumer and Physician Preferences

The shift away from older drugs like Cholybar was driven by consumer and physician preferences for more effective and safer treatments. Newer statins offered better outcomes, fewer side effects, and more convenient dosing regimens, making them more appealing to both patients and healthcare providers.

Regulatory and Market Forces

Regulatory approvals and market forces also played a crucial role. The FDA's approval of newer statins and the subsequent marketing efforts by pharmaceutical companies helped to shift market share away from older drugs. Additionally, the high visibility and marketing campaigns of newer drugs contributed to their rapid adoption[4].

Lessons from the History of Cholesterol-Reducing Drugs

Innovation and Supersession

The history of cholesterol-reducing drugs like Cholybar highlights the importance of innovation in the pharmaceutical industry. Truly innovative products can completely decimate a previously successful drug class, as seen with the rise of statins like Zocor and Lipitor[4].

Market Adaptation

Pharmaceutical companies must adapt quickly to changing market dynamics. The decline of Cholybar and similar drugs serves as a cautionary tale about the need for continuous innovation and the risks of complacency in a highly competitive market.

Conclusion

The market dynamics and financial trajectory of Cholybar and similar cholesterol-reducing drugs are characterized by early success followed by rapid decline due to the introduction of more innovative and effective treatments. This story underscores the importance of continuous innovation and adaptation in the pharmaceutical industry.

Key Takeaways

• Early cholesterol-reducing drugs like Cholybar were initially successful but were soon superseded by newer, more effective statins.
• The introduction of generic versions further eroded the market share of older drugs.
• Consumer and physician preferences for safer and more effective treatments drove the shift away from older drugs.
• Regulatory approvals and market forces significantly influenced the adoption of newer drugs.
• Continuous innovation is crucial for pharmaceutical companies to remain competitive.

FAQs

What was Cholybar used for?

Cholybar was used to reduce cholesterol levels, but it has been largely replaced by more effective statins.

Why did Cholybar lose market share?

Cholybar lost market share due to the introduction of newer, more effective statins like Zocor and Lipitor.

What is the current status of Cholybar in the market?

Cholybar is no longer a dominant player in the cholesterol-reducing drug market, having been superseded by newer treatments.

How did generic competition affect Cholybar?

Generic competition further reduced the market share of Cholybar, but it was the introduction of more innovative brand-name drugs that was the primary cause of its decline.

What lessons can be learned from the history of Cholybar?

The history of Cholybar highlights the importance of innovation and the need for pharmaceutical companies to adapt quickly to changing market dynamics.

Sources

1. Boston Federal Reserve - "Too Much of a Good Thing Can Be Bad"
2. NCBI - "An Historical Review of Steps and Missteps in the Discovery of Anti-Obesity Medications"
3. Baron Capital Group - "A Multi-Billion-Dollar Drug Market"
4. Boston Federal Reserve - "Too Much of a Good Thing Can Be Bad"